



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 31.07.2021

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th Floor  
Plot No.62, G- Block, Opp Trident Hotel,  
Bandra Kurla Complex, Bandra (E)  
Mumbai — 400 098

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 31<sup>st</sup> July, 2021 -- Reg.

Ref: Disclosure under Regulation 30 and 33 SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Saturday, 31<sup>st</sup> July, 2021 had inter-alia transacted and approved the following items of business:

1. Approved the Un-audited Financial Results for the Quarter ended 30<sup>th</sup> June, 2021.
2. Approved the Notice of the 27<sup>th</sup> Annual General Meeting and the 27<sup>th</sup> AGM will be held on Friday, the 24<sup>th</sup> day of September, 2021 at 3.00 P.M. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM').
3. The Register of Members and share transfer registers will be closed from Saturday, 18<sup>th</sup> September, 2021 to Friday, 24<sup>th</sup> September, 2021 (both the days inclusive) and the record date (cut-off date) will be 17<sup>th</sup> September, 2021.
4. The board recommended the reappointment of Sri. P.L.V. Subba Rao, as a director of the company, who retires by rotation, subject to the approval of shareholders at the ensuing Annual General Meeting.
5. The board recommended the appointment of Smt. Shilpa Bung, as an independent Director of the company with effect from 10<sup>th</sup> February, 2021, subject to the approval of the Shareholders at the ensuing 27<sup>th</sup> Annual general meeting of the company.



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

6. The board recommended the appointment of Ms. Sridevi Madati, as an independent Director of the company for the approval of Shareholders at the ensuing 27<sup>th</sup> Annual General Meeting of the company.

7. Approved the Directors report of the company.

We herewith enclose the following:

A. Un-Audited financial Results along with Limited Review Report of the Statutory Auditors for the quarter ended 30<sup>th</sup> June, 2021.

B. Brief profile of Miss. Sridevi Madati (DIN: 02446610), who is proposed to be appointed as an Independent Director of the company.

Kindly take the above on your records

Thanking you,

Yours Faithfully,  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary

The meeting Commenced at 4: 00 PM  
The Meeting Concluded at 5: 10 PM

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Unaudited Financial Results For The Quarter Ended 30th June, 2021

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2021	30.06.2020	31.03.2021	31.03.2021
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Revenue from operations	75.26	84.61	78.32	347.61
2	Other income	8.49	1.54	15.32	38.09
3	Total Income (1+2)	83.75	86.15	93.64	385.70
4	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-
	c) Change in Inventories	-	-	-	-
	d) Employee benefits expense	6.52	5.30	9.59	28.97
	e) Finance costs	-	-	-	-
	f) Depreciation and amortization expense	4.18	4.14	4.14	16.58
	g) Other expenses	3.65	2.68	19.64	26.50
	Total Expenses	14.35	12.12	33.37	72.05
5	Profit/(loss) before exceptional items and tax (3-4)	69.40	74.03	60.27	313.65
6	Exceptional Items	-	-	-	-
7	Profit/(Loss) before tax (5-6)	69.40	74.03	60.27	313.65
8	Tax expense				
	(a) Current tax	6.43	5.75	13.55	39.88
	(b) Deferred tax	(0.14)	0.20	-	(1.64)
	Total Tax Expense	6.29	5.95	13.55	38.24
9	Profit/(Loss) for the Period (7-8)	63.11	68.08	46.72	275.41
10	Other Comprehensive income (OCI)				
	(a) Items that will not be reclassified to profit or loss	94.74	158.32	30.66	414.42
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	0.03	0.03
	Tax on Items that will not be reclassified to profit or loss	-	-	(0.01)	(0.01)
	(c) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive income	94.74	158.32	30.68	414.44
	Total Comprehensive income (9+10)	157.85	226.40	77.40	689.85
11	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	1,946.19
13	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))				
	(1) Basic	0.93	1.01	0.69	4.08
	(2) Diluted	0.93	1.01	0.69	4.08

Segment wise Revenue, Results and Capital Employed for the Quarter Ended 30th June, 2021

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2021	30.06.2020	31.03.2021	31.03.2021
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Segment Revenue				
	a) Bulk Drugs and Intermediates (Lease Rents)	20.00	19.00	40.00	116.50
	b) Investments	63.75	67.15	53.64	269.20
	Total	83.75	86.15	93.64	385.70
	Less: Inter Segment Revenue	-	-	-	-
	Net sales/Income from Operations	83.75	86.15	93.64	385.70
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment				
	a) Bulk Drugs and Intermediates (Lease Rents)	15.24	14.33	35.35	98.56
	b) Investments	63.75	67.15	53.64	269.20
	Total	78.99	81.48	88.99	367.76
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	9.59	7.45	28.72	54.11
	(iii) Un-allocable income	-	-	-	-
	Total Profit Before Tax	69.40	74.03	60.27	313.65
3	Capital Employed (Segment assets – Segment liabilities)				
	a) Bulk Drugs and Intermediates	659.75	578.89	620.95	620.95
	b) Investments	2,175.34	1,634.90	2,056.29	2,056.29
	Total	2,835.09	2,213.79	2,677.24	2,677.24

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 31st July, 2021. These financial results are also available on the website of Metropolitan Stock Exchange of India Limited ([www.msei.in](http://www.msei.in)) and also on the website of the Company ([www.sl1lab.com](http://www.sl1lab.com)).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The outbreak of COVID-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a significant decrease in the economic activities. Given the dynamic nature of the pandemic situation, the carrying value of the Company's investments, trade receivables and loans as at June 30, 2021, may be affected by the severity and duration of the outbreak; however the Company believes that it has taken into account all the possible impact of known events arising out of COVID-19 pandemic in the preparation of financial results resulting out of fair valuation of these investments and impairment of financial instruments. However the impact assessment of COVID-19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes to future economic conditions.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board  
for Sigachi Laboratories Limited

Digitally signed by  
Tunuguntla  
Raja Sekhar  
Date: 2021.07.31  
17:11:30 +05'30'

(T.R.Sekhar)  
Executive Director  
DIN:02943146

Place : Hyderabad  
Date : 31.07.2021

**INDEPENDENT AUDITORS' REVIEW REPORT**


To  
The Board of Directors,  
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sigachi Laboratories Limited** ("the company") for the quarter ended 30<sup>th</sup> June, 2021 and year to date results for the period from 1<sup>st</sup> April, 2021 to 30<sup>th</sup> June, 2021, ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 31.07.2021



For Niranjana & Narayan  
Chartered Accountants  
FRN:005899S

  
M. Niranjana  
Partner, Memb.No.029552  
UDIN: 21029552AAAAHO8179



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

## Brief profile of Ms. Sridevi Madati is as follows:

Ms. Sridevi Madati aged about 44 years, has studied B.com., and also did her graduation in law and She is a Qualified Company Secretary & a member of Institute of Company Secretaries of India (ICSI) and registered member of Independent Directors Data bank as maintained by Indian Institute of Corporate Affairs (IICA), Ministry of Corporate Affairs, Government of India. She has more than 17 years of experience in corporate, secretarial affairs, legal, regulatory matters, compliance and liaison assignments and had been associated with listed and non-listed Companies, NGO's in various capacities spanning from Company Secretary, Head of legal and secretarial Department, Independent Director, Consultant, advisor etc.,. At present she is practicing as a Company Secretary and also as an Insolvency Professional.

*S. Sridevi*

---

Regd. Office : S. No. 530 & 534, Bonthapally - 502 313, Sangareddy Dist., (Telangana) INDIA.